<DOC>
	<DOCNO>NCT00542048</DOCNO>
	<brief_summary>The primary objective study CT 4003 ass behavior EndoTAG®-1 body ( make so-called pharmacokinetic profile ) . Therefore , course drug body examine , i.e . amount speed drug uptake well distribution elimination drug investigate . Further objective study assess effect EndoTAG®-1 liver metastases concern size blood supply measure image technique ( contrast-enhanced ultrasound magnetic resonance image well duplex sonography ) ass effect blood marker indicator destruction neoplasm blood vessel ( so-called marker angiogenesis ) .</brief_summary>
	<brief_title>A Trial Evaluating Pharmacokinetics Mode Action EndoTAG®-1 Tumor Patients With Hepatic Metastases</brief_title>
	<detailed_description>Liver metastases among frequent neoplasm liver represent quite uniform clinical entity regardless carcinoma originate . The treatment dependent number size hepatic lesion still , none therapeutic option lead satisfy result . The growth tumor metastases dependent blood vessel , supply tumor metastases nutrient . Liver metastases , independent original tumor come , especially well supplied blood . The aim treatment investigational medicinal product EndoTAG®-1 target blood vessel , supply metastasis , destroy . Consequently , metastasis damage .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Unresectable hepatic metastasis carcinomatous origin exception HCC , biliary bile duct carcinoma At least one measurable hepatic metastasis &gt; 20 mm diameter ( measure MRI ) Last application palliative chemotherapy ( drug dependent primary tumor ) least 7 day ago Gender : male female ( least 6 individual gender ) Age &gt; = 18 year Negative pregnancy test ( female childbearing potential ) Willingness perform doublebarriercontraception study 6 month post study medication ECOG performance status 0,1 2 Assumed life expectancy &gt; 3 month Signed informed consent History significant liver pathology ( metastasis , e.g . cirrhosis liver , PSC , PBC ) liver transplantation Laboratory test ( hematology , chemistry ) outside specific limit : ANC &lt; = 1.0 x 10^9/L Platelets &lt; = 100 x 10^9/L Hb &lt; = 9.0 g/dL ( &lt; = 5.6 mmol/L ) Total Bilirubin &gt; 2.0 mg/dL Serum Creatinine &gt; 1.5 mg/dL Renal insufficiency GFR &lt; 60 mL/min Currently ongoing taxanecontaining palliative chemotherapy regimen history taxane administration within 4 week prior study entry Pregnancy nursing status Positive HIV , HBV HCV test The patient contraindication MRI CEUS accord accepted clinical guideline Known hypersensitivity component EndoTAG®1 formulation , gadoliniumbased MRcontrast medium sulphur hexafluoride Claustrophobia history active significant neurological disorder and/or psychiatric disorder would prohibit understanding give informed consent , would interfere clinical radiological evaluation patient trial Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Hepatic metastasis</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>EndoTAG-1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Metastases liver</keyword>
</DOC>